Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best cheap biotech stocks to buy now. On February 25, Deutsche Bank adjusted the price target on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) to $30 from $31 and reiterated a Hold rating on the shares, updating its model on the stock post the fiscal Q4 report.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported strong 2025 financial results on February 24, with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. It generated net product revenue of $868.5 million for the full year 2025, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) further stated that WAKIX is on track to exceed $1 billion in revenue and attain blockbuster status in 2026, which highlights the strength and durability of the pitolisant franchise. Management reported that the average number of patients on WAKIX rose by ~400 patients to ~8,500 patients in fiscal Q4 2025, marking the third consecutive quarter of ~400+ patient adds.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors.

While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.